Psychedelic drug development is moving into a more consequential phase. Compounds such as MDMA, psilocybin, LSD, and other psychoactive agents continue to be explored for serious mental health conditions, including post-traumatic stress disorder, treatment-resistant depression, major depressive disorder, and substance use disorders. The therapeutic promise remains compelling, particularly in areas where patients continue to face... The post Psychedelic Drug Development: Clinical Trial Design and